

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : James E. Galen) Group Art Unit 1645
App. No. : 09/993,292)
Filed : November 23, 2001)
For : USE OF CLYA HEMOLYSIN)
FOR EXCRETION OF PROTEINS)
Examiner : Unassigned)

RECEIVED

JUL 29 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 22 Jul 2002By: 

James J. Mullen III, Ph.D.

Registration No. 44,957

Attorney of Record


620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

(619) 235-8550

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. UOFMD.007A	APPLICATION NO. 09/993,292
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Galen	
		FILING DATE November 23, 2001	
		GROUP 1645	



RECEIVED

JUL 29 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	4,235,877	11/25/80	Fullerton			
	2	4,355,117	10/19/82	Antrim et al.			
	3	4,372,945	2/8/83	Likhite			
	4	4,474,757	10/2/84	Arnon et al.			
	5	4,665,027	5/12/87	Dale et al.			
	6	4,910,139	3/20/90	Chang et al.			
	7	5,387,744	2/7/95	Curtiss III, et al.			
	8	5,512,480	4/30/96	Sandstrom et al.			
	9	5,525,504	6/11/96	Goebel et al.			
	10	5,585,266	12/17/96	Plitt et al.			
	11	5,635,368	6/3/97	Lommi et al.			
	12	6,413,768	7/2/02	Galen			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	13	Atkins, A., N. R. Wyborn, A. J. Wallace, T. J. Stillman, L. K. Black, A. B. Fielding, M. Hisakado, P. J. Artymiuk, and J. Green. 2000. Structure-function relationships of a novel bacterial toxin, hemolysin E. The role of <i>g</i> . J. Biol. Chem. 275:41150-41155.
	14	Bramucci, M. G. and V. Nagarajan. 1996. Direct selection of cloned DNA in <i>Bacillus subtilis</i> based on sucrose-induced lethality. Appl. Environ. Microbiol. 62:3948-3953.
	15	Corchero, J. L. and A. Villaverde. 1998. Plasmid maintenance in <i>Escherichia coli</i> recombinant cultures is dramatically, steadily, and specifically influenced by features of the encoded proteins. Biotechnol. Bioeng. 58:625-632.
	16	Cserjan-Puschmann, M., W. Kramer, E. Duerrschmid, G. Streidner, and K. Bayer. 1999. Metabolic approaches for the optimisation of recombinant fermentation processes. Appl. Microbiol. Biotechnol. 53:43-50.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. UOFMD.007A	APPLICATION NO. 09/993,292
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Galen	
(USE SEVERAL SHEETS IF NECESSARY)		AGING DATE November 23, 2001	GROUP 1645

RECEIVED
JUL 29 2002
TECH CENTER 1600/2900

O I P E
JUL 25 2002
PATENT & TRADEMARK OFFICE

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	17	del Castillo, F. J., S. C. Leal, F. Moreno, and I. del Castillo. 1997. The <i>Escherichia coli</i> K-12 <i>sheA</i> gene encodes a 34-kDa secreted haemolysin. Mol. Microbiol. 25 :107-115.
	18	Galen, J. E. and M. M. Levine. 2001. Can a 'flawless' live vector vaccine strain be engineered? Trends in Microbiology 9 :372-376.
	19	Hess et al., Feb. 1996, <i>Superior efficacy of secreted over somatic antigen display in recombinant salmonella vaccine induced protection against listeriosis</i> , Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 1458-1463
	20	Ludwig, A., S. Bauer, R. Benz, B. Bergmann, and W. Goebel. 1999. Analysis of the SlyA-controlled expression, subcellular localization and pore-forming activity of a 34 kDa haemolysin (ClyA) from <i>Escherichia coli</i> K-12. Mol. Microbiol. 31 :557-567.
	21	Wallace, A. J., T. J. Stillman, A. Atkins, S. J. Jamieson, P. A. Bullough, J. Green, and P. J. Artymiuk. 2000. <i>E. coli</i> hemolysin E (HlyE, ClyA, SheA): X-ray crystal structure of the toxin and observation of membrane pores by electron microscopy. Cell 100 :265-276.

S:\DOCS\JMJM\JMJM-8178a.DOC
071902

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	